Royalty Pharma CEO Pablo G. Legorreta Receives 65,216 Shares

What Happened
Pablo G. Legorreta, CEO, Chairman and a director of Royalty Pharma plc (RPRX), received 65,216 Class A ordinary shares on 2026-08-05 as the settlement of Equity Performance Awards (reported as an exempt acquisition). He also disposed of 30,000 shares by gift on 2026-08-07. Both transactions were reported on a Form 4 filed 2026-08-07. The reported acquisition was at $0 (award), and the gift was reported at $0.

Key Details

• Transaction dates and specifics:
  • 2026-08-05: Award/acquisition — 65,216 Class A shares @ $0.00 (exempt settlement of Equity Performance Awards; footnote F1).
  • 2026-08-07: Gift/disposition — 30,000 shares @ $0.00 (derivative gift).
• Net change in directly reported Class A shares from these entries: +35,216 shares (65,216 acquired, 30,000 gifted).
• Holdings noted in the filing (additional to the Class A shares above):
  • Family vehicles controlled by Legorreta hold 9,700,000 Class B ordinary shares exchangeable into 9,700,000 Class A shares and 13,356,742 Class E ordinary shares of Holdings exchangeable into 13,356,742 Class A shares (Class E shares subject to vesting).
  • Footnotes F2–F3: certain limited partnership interests (RPI US LP Interests) and Class B/Class E interests are exchangeable into Class A shares for no additional value under the company’s exchange agreements.
• Filing timeliness: Form 4 was filed on 2026-08-07 for transactions on 2026-08-05 and 2026-08-07 (no indication of a late filing in the record).

Context

• The 65,216-share entry is an equity award settlement (routine compensation / incentive award), not an open-market purchase; such awards are common for executives and don’t necessarily signal a new view on the stock.
• The 30,000-share gift is a non-market disposition and likewise does not directly reflect trading sentiment.
• The filing also highlights convertible holdings (Class B/E and partnership interests) that can be converted into Class A shares for no additional value, which represents additional potential dilution/conversion but may be subject to vesting or other terms.